Pioneering Bispecific Nanobody Targeting CLEC9A and SARS-CoV-2 E2 Glycoprotein for Innovative COVID-19 Therapeutics

VHH-P260 is an advanced, biologically engineered humanized nanobody in development targeting both C-type lectin domain containing 9A (CLEC9A) and E2 glycoprotein precursor. Designed as a bispecific trimerbody, VHH-P260 aims to provide a novel therapeutic strategy for SARS-CoV-2 Infection (COVID-19). Currently in the Biological Testing phase, this candidate leverages precise targeting of immune system components and viral structures, offering distinct potential to address unmet needs in the management of COVID-19 through innovative immune engagement and viral neutralization mechanisms.

Licensing Opportunity

VHH-P260 is currently available for licensing and partnership opportunities. We welcome inquiries from collaborators and industry partners interested in advancing this promising bispecific nanobody toward clinical and commercial success.

Development Phase

Modality

VHH-P260 is a bispecific trimerbody consisting of three single-chain antibody fragments against the human dendritic cell natural killer group receptor-1, connected via flexible linkers to a homotrimerization domain derived from human collagen XVIII. This structural platform is further extended by attaching three single-domain antibodies specific for the receptor binding domain of the SARS-CoV-2 E2 glycoprotein precursor. The modular nanobody architecture imparts considerable benefits, such as enhanced tissue penetration, increased stability, and multivalent binding. The compact size and robust structure of the nanobody components facilitate effective targeting of both immune and viral elements, providing a pharmacological profile well-suited for intervention in SARS-CoV-2 infection.

Target

CLEC9A and E2 glycoprotein precursor are critical molecular targets in the context of immune modulation and viral neutralization. CLEC9A, a C-type lectin receptor, is primarily expressed on dendritic cells, playing a pivotal role in antigen presentation and initiation of immune responses. E2 glycoprotein precursor pertains to viral entry machinery, crucial for host cell infection. Targeting CLEC9A may bolster antigen-specific responses, while engagement with E2 glycoprotein precursor can directly impede viral infectivity. VHH-P260 strategically binds both CLEC9A and E2 glycoprotein precursor, optimizing immune redirection and viral blockade. This dual-targeting approach leverages the unique biological functions of CLEC9A and E2 glycoprotein precursor, representing a promising proprietary asset for next-generation COVID-19 therapeutics.

Mechanism of Action

VHH-P260 exerts its effects through dual mechanisms: it binds CLEC9A, facilitating myeloid cell engagement and potential enhancement of antigen-specific immune responses, and it targets the E2 glycoprotein precursor, acting as a viral fusion inhibitor by preventing the interaction of SARS-CoV-2 with host cells. As a myeloid-cell engager, VHH-P260 may promote the activation and recruitment of immune cells to sites of infection. Its bispecific nature enables it to coordinate immune defense while simultaneously neutralizing viral particles. Furthermore, the nanobody platform underlying VHH-P260 offers a versatile backbone for future development of antibody-drug conjugates or additional multispecific immunotherapeutics, expanding its translational and commercial potential.

SARS-CoV-2 Infection (COVID-19)

SARS-CoV-2 infection, widely known as COVID-19, has triggered a global public health crisis with significant socio-economic impact. Characterized by respiratory and systemic manifestations, the disease is caused by a novel coronavirus and has resulted in widespread morbidity and mortality worldwide. Current treatment approaches include antiviral agents, immune modulators, and supportive care. However, limitations persist due to the emergence of viral variants, suboptimal efficacy in certain patient populations, resistance, and the lack of accessible, broadly effective therapies. The need for innovative therapeutics capable of engaging both immune mechanisms and providing direct antiviral activity remains substantial. VHH-P260, with its dual-targeting of CLEC9A and E2 glycoprotein precursor, offers a potential breakthrough, combining immune engagement with viral neutralization in a highly stable, scalable nanobody format, representing a strong candidate to address these persistent challenges in SARS-CoV-2 infection management.